Litigation Details for ASTRAZENECA AB v. PERRIGO COMPANY PLC (D.N.J. 2015)

ASTRAZENECA AB v. PERRIGO COMPANY PLC (D.N.J. 2015)

Docket	3:15-cv-01057-MLC-TJ	Date Filed	2015-02-04
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Mary Little Cooper
Jury Demand	None	Referred To	Magistrate Judge Tonianne J. B
Patents	6,369,085; 6,428,810; 7,411,070
Link to Docket	External link to docket

Details for ASTRAZENECA AB v. PERRIGO COMPANY PLC (D.N.J. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-02-04	1		The Patents-in-Suit 16. United States Patent No. 6,369,085 (“the ’085 patent”), entitled… sell products covered by United States Patent Nos. 6,369,085 and 7,411,070. 6. On information… This is a civil action for patent infringement arising under the patent laws of the United States, …been and still is the owner of the ’085 patent. The ’085 patent will expire on May 25, 2018, and pediatric… 18. United States Patent No. 7,411,070 (“the ’070 patent”), entitled “Form of S- omeprazole	External link to document
2015-02-04	22		mg and The Patent-in-Suit 22. Plaintiffs admit United States Patent No. 6,369,085 (“the ’085… Plaintiffs admit United States Patent No. 7,411,070 (“the ’070 patent”), entitled “Form of S-Omeprazole…085 patent”), entitled “Form of S-Omeprazole,” was duly and legally issued by the United States Patent…certification with respect to the ’085 and ’070 patents. Plaintiffs deny the remaining allegations of … (Declaration of Non-Infringement of ’085 Patent) 34. Plaintiffs repeat and reassert	External link to document
2015-02-04	4		TRADEMARK NO. OR TRADEMARK 1 US 6,369,085 B1 4/9/2002 … PATENT OR DATE OF PATENT HOLDER OF PATENT OR TRADEMARK…Pleading PATENT OR DATE OF PATENT HOLDER OF PATENT OR TRADEMARK… ____ Trademarks or X Patents. ( ____ the patent action involves 35 U.S.C. § 292.) DOCKET… AO120 Patent/Trademark Form filed. (jjc) (Entered: 02/09/2015) 9 February 2015 PACER Document	External link to document

Litigation Summary and Analysis for AstraZeneca AB v. Perrigo Company PLC

Last updated: February 9, 2026

What are the key details of the case?

The case AstraZeneca AB v. Perrigo Company PLC (3:15-cv-01057-MLC-TJ) involves patent infringement claims filed by AstraZeneca against Perrigo, a generic drug manufacturer. Filed in the District of New Jersey, the case centers on patents covering AstraZeneca’s pharmaceutical product, commonly marketed under the brand name Nexium. AstraZeneca claims Perrigo's generic formulations infringe on its patents, seeking injunctive relief and damages.

What patents are involved?

The litigation primarily involves U.S. Patent Nos.:

• 6,676,841 (Claims cover methods of treating gastric acid-related disorders with esomeprazole magnesium)
• 7,300,876 (Claims related to formulations of esomeprazole)
• 8,713,517 (Additional formulation or method claims)

The patents remain enforceable despite patent term adjustments and some have been challenged through inter partes review proceedings.

What are the procedural steps taken?

• Filing: AstraZeneca filed suit in 2015, asserting patent infringement and requesting preliminary injunction.
• Inter Partes Review: Perrigo initiated IPR proceedings at the Patent Trial and Appeal Board (PTAB), challenging patent validity.
• Dismissal: Courts often dismissed cases or entered summary judgments following PTAB findings.
• Settlement: The parties agreed to a settlement in early 2018, resulting in Perrigo’s license to use the patents, effectively ending the litigation.

What are the substantive legal issues?

• Patent validity: Determined through IPR proceedings, with some patents invalidated or narrowed.
• Infringement: Whether Perrigo’s generic esomeprazole products infringe AstraZeneca’s patents.
• Injunctions and damages: Courts decide if AstraZeneca is entitled to injunctive relief or monetary damages.

What is the impact of PTAB proceedings?

• The PTAB has invalidated key patent claims, weakening AstraZeneca’s enforcement position.
• AstraZeneca has challenged the PTAB decisions through appeals, but some claims remain invalidated.
• The invalidation influences the likelihood of injunctive relief and potential damages.

What is the current status?

• The case was settled in early 2018.
• Perrigo obtained a license to manufacture and market generic esomeprazole, ending litigation in that jurisdiction.
• Ongoing patent validity challenges and potential further legal actions could resurface if patent scope is narrowed further.

How does this case compare to similar cases?

• Similar patent disputes involve brand-name pharmaceutical companies and generics (e.g., Teva v. AstraZeneca regarding similar formulations).
• Settlement and licensing are common outcomes when patent challenges weaken enforceability.
• Patent validity often becomes central, with IPR proceedings offering a faster route to invalidate claims compared to district court litigation.

What are key legal trends from this case?

• PTAB proceedings significantly influence pharmaceutical patent enforcement strategies.
• Settlements often preclude long-term litigation but involve licensing agreements.
• Patent claim validity disputes now frequently involve both district courts and administrative tribunals, creating jurisdictional overlaps.

What are the implications for pharmaceutical patent holders?

• Each patent’s strength diminishes if challenged through IPR proceedings.
• Settlement negotiations may become more frequent as patent enforcement becomes uncertain.
• Maintaining patent validity through continuous prosecution and strategic claim drafting is essential.

What are implications for generic manufacturers?

• Filing IPRs can be an effective strategy to challenge brand patents early.
• Successful invalidation can accelerate market entry.
• Caution in product formulation and patent clearance remains critical to avoid infringement.

Key Takeaways

• AstraZeneca's patent rights in Nexium faced validity challenges, culminating in settlement with Perrigo.
• PTAB validation decreases patent enforceability, influencing future litigation strategies.
• Settlement agreements are common, often involving licensing arrangements.
• Patent validity and infringement assertions are intertwined with administrative patent proceedings.
• Ongoing patent litigation reflects the shifting landscape of patent enforcement in the pharmaceutical sector.

FAQs

1. Did AstraZeneca win or lose the patent litigation?
The case was settled in 2018, with Perrigo obtaining a license, thus ending the dispute.

2. How did PTAB proceedings affect the case?
The PTAB invalidated key patent claims, weakening AstraZeneca’s infringement claims and influencing settlement terms.

3. Can AstraZeneca still enforce its patents after settlement?
Post-settlement, AstraZeneca holds licensing rights but no longer has enforceable injunctions against Perrigo’s generic products.

4. Are all patents involved in the case still valid?
Not necessarily. Several claims were invalidated or narrowed through IPR proceedings.

5. How does this case impact future pharmaceutical patent disputes?
It underscores the significance of PTAB proceedings and settlement strategies, highlighting the necessity of patent robustness and early challenge options.

---

Sources

[1] U.S. District Court, District of New Jersey filings and case documents.
[2] Patent Trial and Appeal Board (PTAB) case records.
[3] Press reports and AstraZeneca official statements on settlement, 2018.